TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06033092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen 10 mg Tablet
Description: One tablet of Tamoxifen 10 mg every other day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen 10 mg Tablet
Description: One tablet of Tamoxifen 10 mg every other day for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent caloric restriction
Description: 5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent caloric restriction
Description: 5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)
Study: NCT04546295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brushlink application
Description: Brushlink application + Interproximal brush

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water-flosser
Description: Water-flosser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interproximal brush
Description: Interproximal brush alone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interproximal brush
Description: Interproximal brush alone
Study: NCT06033092

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step counter Device
Description: Participants will receive personal advice on healthy lifestyle and a step counter

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Step counter Device
Description: Participants will receive personal advice on healthy lifestyle and a step counter
Study: NCT04546295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interproximal brush
Description: Interproximal brush alone
Study: NCT04888195

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
Study: NCT05326672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benvitimod Cream
Description: Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
Study: NCT04957277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: load modulation
Description: Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
Study: NCT04406532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT-Pal
Description: Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness.
Study: NCT05326672

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 8 weeks after enrolment.
Study: NCT06012266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin Tablets
Description: Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin Tablets
Description: Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)
Study: NCT04406532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided exercises
Description: Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness.
Study: NCT05268744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrient
Description: Subject will take micronutrient supplement daily for 8 weeks
Study: NCT04341987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief Imagery Rehearsal Therapy
Description: Two-sessions of behaviorally-based imagery rehearsal therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
Study: NCT06101602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching with Floss Band
Description: Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Stretching without Floss Band
Description: In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
Study: NCT06356441

Intervention type: DIAGNOSTIC_TEST
Intervention: AI
Description: An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
Study: NCT05601271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 100 to 300 mg a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 100 to 300 mg a day for 3 months
Study: NCT05514093

Intervention type: DEVICE
Intervention: Beyond Silence App
Description: The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization.
Study: NCT04880499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid, vitamin B2, B6, B12, C, and E
Description: A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
Study: NCT05910983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar enucleation of the prostate (BipolEP)
Description: Bipolar enucleation of the prostate (BipolEP)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar enucleation of the prostate (BipolEP)
Description: Bipolar enucleation of the prostate (BipolEP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical Botox injection
Description: Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
Study: NCT05309499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose
Description: ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulphate
Description: ferrous sulphate is oral iron, 121patiants will be randomised to this group
Study: NCT04984811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efineptakin alfa
Description: 1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
Study: NCT06168929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640, 2.5mg\*4 - 10mg\*1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640, 10mg\*1 - 2.5mg\*4
Study: NCT05067829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four(TOF)
Description: Train of four(TOF) monitoring after anesthesia induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four(TOF)
Description: Train of four(TOF) monitoring after anesthesia induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four(TOF)
Description: Train of four(TOF) monitoring after anesthesia induction
Study: NCT04564248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website access
Description: website access will be provide to families
Study: NCT06225947

Intervention type: DRUG
Intervention: Lemborexant 5 MG
Description: The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
Study: NCT06120595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REBECCA-assisted intervention 1
Description: The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REBECCA-assisted intervention 2
Description: The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: Standard follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard follow-up
Description: Standard follow-up
Study: NCT06293170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DETECT
Description: DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: Conventional care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional care
Description: Conventional care
Study: NCT05983276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
Study: NCT04555226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node dissection
Description: Open/minimaly invasive pelvic and para-aortic lymph node dissection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiation
Description: 1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~3. Target doses for the image-positive nodes can range from 55 to 60Gy~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: Pathlogical positive para-aortic lymph node~3. Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed.
Study: NCT04884256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-004
Description: Dose response study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-004
Description: Dose response study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBT-004
Description: Dose response study
Study: NCT05991518

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection of IAH0968+Gemcitabine+Cisplatin
Description: Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection of IAH0968+Gemcitabine+Cisplatin
Description: Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
Study: NCT05714657

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Shortened Course Adjuvant Radiotherapy Following TORS
Description: Shortened Course Adjuvant Radiotherapy Following TORS
Study: NCT05631886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TP53-EphA-2-CAR-DC
Description: 5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Intravenous abraxane 125 mg/m\^2/day on day-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Intravenous anti-PD-1 antibody 200 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 Monoclonal Antibody
Description: Intravenous anti-CTLA4 antibody 1 mg/kg/day
Study: NCT06137404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Comparison of splints for trigger finger

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Comparison of splints for trigger finger
Study: NCT05534750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid arm (SIVEXTRO®)
Description: Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid arm (ZYVOXID®)
Description: Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Study: NCT05991518

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine+Cisplatin
Description: Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
Study: NCT04510844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
Study: NCT05858567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.